Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason I Herschkowitz

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|June 3, 2011
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cellsJason I Herschkowitz, Wei Zhao, Mei Zhang, et al.
Genome Biology|November 14, 2013
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterpartsAdam D Pfefferle, Jason I Herschkowitz, Jerry Usary, et al.
Cancer Cell|December 11, 2007
ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complexZhe Li, Cristina E Tognon, Frank J Godinho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2013
Predicting drug responsiveness in human cancers using genetically engineered miceJerry Usary, Wei Zhao, David Darr, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2010
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypesJoseph H Taube, Jason I Herschkowitz, Kakajan Komurov, et al.
Cancer Research|February 5, 2013
FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancerBrett G Hollier, Agata A Tinnirello, Steven J Werden, et al.
Scientific Reports|September 19, 2013
Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell propertiesJoseph H Taube, Gabriel G Malouf, Emily Lu, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2013
Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancerJennifer F Knight, Robert Lesurf, Hong Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2011
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivoKristen L Meerbrey, Guang Hu, Jessica D Kessler, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresChad J Creighton, Xiaoxian Li, Melissa Landis, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|June 3, 2011
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cellsJason I Herschkowitz, Wei Zhao, Mei Zhang, et al.
Genome Biology|November 14, 2013
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterpartsAdam D Pfefferle, Jason I Herschkowitz, Jerry Usary, et al.
Cancer Cell|December 11, 2007
ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complexZhe Li, Cristina E Tognon, Frank J Godinho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2013
Predicting drug responsiveness in human cancers using genetically engineered miceJerry Usary, Wei Zhao, David Darr, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2010
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypesJoseph H Taube, Jason I Herschkowitz, Kakajan Komurov, et al.
Cancer Research|February 5, 2013
FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancerBrett G Hollier, Agata A Tinnirello, Steven J Werden, et al.
Scientific Reports|September 19, 2013
Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell propertiesJoseph H Taube, Gabriel G Malouf, Emily Lu, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2013
Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancerJennifer F Knight, Robert Lesurf, Hong Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2011
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivoKristen L Meerbrey, Guang Hu, Jessica D Kessler, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresChad J Creighton, Xiaoxian Li, Melissa Landis, et al.
Pageof 5